Search - tctmd.com

Displaying 21 - 40 of 49

Sort: Relevancy | Date

Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity

News Daily News

Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity

April 17, 2024

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

April 12, 2024

FDA Grants MACE Reduction Indication for Semaglutide

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

March 08, 2024

One in Three Overweight MI Patients May Benefit From Semaglutide

News Daily News

One in Three Overweight MI Patients May Benefit From Semaglutide

February 26, 2024

Injectable Semaglutide Shortage Forces Physicians to Pivot

News Daily News

Injectable Semaglutide Shortage Forces Physicians to Pivot

February 05, 2024

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

February 02, 2024

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

January 12, 2024

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients

News Conference News AHA 2023

Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients

November 14, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

News Daily News

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

September 12, 2023

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

News Daily News

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

August 08, 2023

Total Meals, Not Timing, Drives Long-term Body Weight Changes

News Daily News

Total Meals, Not Timing, Drives Long-term Body Weight Changes

January 24, 2023

Intermittent Fasting Trial Comes Out (Partly) Positive, but CV Impact Mixed

News Daily News

Intermittent Fasting Trial Comes Out (Partly) Positive, but CV Impact Mixed

August 12, 2022

Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups

News Daily News

Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups

February 01, 2021

INVESTED: No Added CV Benefit From High-Dose Flu Vaccine

News Conference News AHA 2020

INVESTED: No Added CV Benefit From High-Dose Flu Vaccine

November 17, 2020

Bariatric Surgery Tied to Better Long-term Outcomes After MI

News Daily News

Bariatric Surgery Tied to Better Long-term Outcomes After MI

October 27, 2020

Genetics Only Weakly Predicts Midlife BMI for Young Adults

News Daily News

Genetics Only Weakly Predicts Midlife BMI for Young Adults

January 09, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.